Novo Nordisk announced the results of the REDEFINE 4 trial, where their new obesity drug CagriSema did not achieve equivalent efficacy compared to Eli Lilly's tirzepatide.[2] The study was open label and lasted 84 weeks. Patients on CagriSema lost an average of 20.2% of body weight, while patients on tirzepatide (marketed as Zepbound and Mounjaro) lost 23.6%.[2] Statistically, non-inferiority of CagriSema to tirsepatide was not demonstrated.[2] Novo Nordisk shares fell more than 12% on the Copenhagen Stock Exchange, Eli Lilly shares rose 4% before the US open.[2] CagriSema is one of Novo Nordisk's key drugs to improve its position in the competitive obesity drug market.[2]